Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Fenofibrate in Lipoprotein Glomerulopathy: A 20-Year Long Resolution.
Int J Surg Pathol
November 2024
Lipoapheresis Unit, Reference Center for Diagnosis and Treatment of Inherited Dyslipidemias. Fondazione Toscana Gabriele Monasterio, Pisa, Italy.
First patient diagnosed with lipoprotein glomerulopathy and Alport syndrome.
Nephrology (Carlton)
December 2024
Department of Pediatrics, West China Second University Hospital, Sichuan University, Chengdu, Sichuan Province, China.
Article Synopsis
- - Alport syndrome (AS) is a common genetic kidney disorder resulting from mutations in COL4A3, COL4A4, and COL4A5 genes, leading to abnormal collagen IV structure and function.
- - Lipoprotein glomerulopathy (LPG) is another inherited condition linked to mutations in the APOE gene, affecting lipid metabolism.
- - A case is reported of an 11-year-old girl with both AS and LPG, exhibiting various symptoms and laboratory findings, and genetic tests identified specific pathogenic variants; the study highlights the need for early renal biopsy and whole-exome sequencing for accurate diagnosis.
Lipoprotein glomerulopathy with a novel apolipoprotein E variant, APOE Kanto (Asp 151dup).
CEN Case Rep
August 2024
Sanko Clinic, Fukuoka, Japan.
A 33-year-old Japanese man was admitted for possible kidney disease because of massive proteinuria. Laboratory findings were characterized by marked urinary protein of 4.7 g/day and high-serum triglyceride levels of 266 mg/dL.
View Article and Find Full Text PDFLipoprotein glomerulopathy with markedly increased arterial stiffness successfully treated with a combination of fenofibrate and losartan: a case report.
BMC Nephrol
May 2024
Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Background: Lipoprotein glomerulopathy (LPG) is a apolipoprotein E (ApoE)-related glomerular disease and has been associated with type III hyperlipidemia. Without appropriate treatment, chronic kidney disease (CKD) caused by LPG progresses, and approximately half of the patients develop end-stage kidney disease within 1-27 years of disease onset. However, few studies have highlighted the clinical course of cardiovascular diseases (CVDs) in patients with LPG.
View Article and Find Full Text PDFClinicopathological characteristics and gene mutations in 11 patients with lipoprotein glomerulopathy.
Ren Fail
December 2024
Renal Division, Department of Medicine, Peking University First Hospital, Beijing, China.
Article Synopsis
- * Eleven patients were analyzed, revealing a high incidence of proteinuria, dyslipidemia, and specific kidney changes observed through biopsies, with most showing mutations in the apolipoprotein E gene.
- * The findings emphasize the importance of kidney biopsies for diagnosis and suggest that treatment with ACEIs or ARBs can help manage the disease progression in LPG patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!